Learn More About Our Innovative Biotechnology

Press Releases

AVM Biotechnology Founder and CSO to Present Company Information and Clinical Trial Progress at Life Science Innovation Northwest

Press Releases

AVM Awarded $1.6 Million Phase II SBIR Grant to Study AVM0703’s Potential to Reverse Type 1 Diabetes

Press Releases

C-Suite Expands in Anticipation of Commercialization

Publications

AVM0703 Tumor Debulking Enhances Cy/Flu Efficacy

Publications

Very-High Dose Dexamethasone Mobilizes Endogenous Bi-Specific Gamma Delta+ NKT Cells

Press Releases

FDA Approves Accelerated Dosing in NHL/Leukemia Clinical Trial

Press Releases

Full Enrollment of First Cohort of Relapsed/Refractory Non-Hodgkin’s Lymphoma Patients dosed with AVM0703

Videos

Theresa Deisher Speaks at ESWI Influenza Conference

Publications

Pharma’s Almanac Features AVM0703

Press Releases

AVM Biotechnology CEO/CSO Selected to Speak at ESWI Conference in Novel and Outstanding Discoveries Track

Videos

What is AVM0703? Find Out!

Press Releases

President Receives Dexamethasone Treatment

Press Releases

AVM Receives FDA Permission for Clinical Trials in COVID-19/ARDS

Press Releases

AVM Expands Executive Team, Appoints Janet R. Rea COO

Videos

Amplifying Scientific Innovation Podcast

Press Releases

AVM’s Dexamethasone Formulation Has Potential For Greater Impact Than Oxford’s

Videos

Oxford/AVM’s potential COVID-19 Treatment Featured on KOMO News

Press Releases

AVM Awarded SBIR Grant From National Cancer Institute

Press Releases

FDA Approves AVM0703 Clinical Trials in R/R Non-Hodgkins Lymphoma

Videos

Cavendish Global 2020

Publications

AVM0703, a New Treatment Option for Lymphoma Patients